Related Experiment Video
Updated: Jul 4, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Genetic profile identification in clinically localized prostate carcinoma
Michele Gallucci1, Roberta Merola, Costantino Leonardo
1Department of Urology, Regina Elena Cancer Institute, Rome, Italy.
Urologic Oncology
|June 7, 2008
Summary
Genetic profiling of prostate cancer in radical prostatectomy patients confirmed previous findings. Adverse genetic profiles, including chromosome aneusomy and gene alterations, correlate with higher stages and progression, aiding in treatment strategy decisions.
Area of Science:
- Oncology
- Genetics
- Urology
Background:
- Prostate cancer characterization is crucial for treatment.
- Previous studies suggested cytogenetic alterations are linked to prostate cancer progression.
Purpose of the Study:
- To confirm previously identified cytogenetic profiles in prostate cancer.
- To evaluate the association between genetic alterations and clinical outcomes in patients undergoing radical prostatectomy.
Main Methods:
- Retrospective analysis of 106 prostate cancer patients treated with surgery (1991-2004).
- Histological evaluation and fluorescence in situ hybridization (FISH) to assess LPL (8p22), c-MYC (8q24) genes, and chromosomes 7, 8, and X.
- Defined an adverse genetic profile based on chromosome aneusomy and gene alterations.
Main Results:
- High prevalence of chromosome 7, 8, and X aneusomy (91.5%, 78.3%, 51.9%) and LPL deletion (76.0%).
- MYC amplification observed in 1.6% of samples.
- Adverse genetic profiles were significantly associated with higher tumor stage (P=0.02), progression (P=0.03), and Gleason grade 4+3 (P=0.02).
- A specific tumor group with chromosome 8 aneusomy, X polysomy, LPL deletion, and high Gleason grade was linked to progression.
Conclusions:
- Previously identified cytogenetic profiles hold predictive power in prostate cancer.
- Genetic profiling can characterize individual patients.
- These genetic assessments may influence postoperative therapeutic strategies for prostate cancer.
